Applied BioMath, LLC Announces Participation at the Thirteenth American Conference on Pharmacometrics

CONCORD, Mass., Oct. 26, 2022 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their participation at the Thirteenth American Conference on Pharmacometrics (ACoP13) occurring October 30th - November 2nd, 2022 in Aurora, CO.

During the pre-conference, Georgi Kapitanov, PhD, Senior Principal Scientist at Applied BioMath will present, "Blinatumomab Trimer Formation - Insights from a Mechanistic PK/PD Model on the Implications for Switching from Infusion to Subcutaneous Dosing Regimen in Acute Lymphoblastic Leukemia" on Sunday, October 30, 2022 from 11:15-11:30 a.m. This work will also be featured as a poster during the pre-conference (poster #S-001).

Also at ACoP13, Sarah Minucci, PhD, Senior Scientist at Applied BioMath will present, "Mathematical Modeling of Ventilator-induced Lung Inflammation" during the Roller Coaster 1 session occurring Wednesday, November 2, 2022 from 9:00-11:00 a.m.

In addition to the presentations, Applied BioMath will present the following posters at ACoP13:

•  Monday, October 31st
• Poster #M-069: Comparison Across Anti-PD-1 Antibodies - Insights from QSP-Based Meta-Analysis
• Poster #M-071: Blinatumomab Trimer Formation - Insights from a Mechanistic PK/PD Model on the Implications for Switching from Infusion to Subcutaneous Dosing Regimen in Acute Lymphoblastic Leukemia
• Tuesday, November 1st
• Poster #T-030: Predicting the Incidence Proportion of Drug-Induced Serotonin Syndrome-Associated Tremors Using a Model-based Meta-Analysis, featuring their collaboration with EMD Serono

"We are looking forward to participating in multiple sessions at ACoP this year," said John Burke, PhD, Co-founder, President and CEO at Applied BioMath. "We appreciate the opportunity to share the breadth of our modeling work. Sharing successes and challenges with our peers is critical to moving the field forward."

To learn more about Applied BioMath, visit www.appliedbiomath.com.

About Applied BioMath
Founded in 2013, Applied BioMath's mission is to revolutionize drug invention. Applied BioMath applies biosimulation, including quantitative systems pharmacology, PKPD, bioinformatics, machine learning, clinical pharmacology, and software solutions to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk therapeutic research and development. Their approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through all phases of clinical trials. The Applied BioMath team leverages their decades of expertise in biology, mathematical modeling and analysis, high-performance computing, and industry experience to help groups better understand their therapeutic, its best-in-class parameters, competitive advantages, patients, and the best path forward into and in the clinic to increase likelihood of clinical concept and proof of mechanism, and decrease late stage attrition rates. For more information about Applied BioMath and its services and software, visit www.appliedbiomath.com.

Applied BioMath and the Applied BioMath logo are registered trademarks of Applied BioMath, LLC.

Press contact:
Kristen Zannella
[email protected]

SOURCE Applied BioMath, LLC